Journals / Pharmata / 2022 / Cilt: 2 Sayı: 4

FIXED-DOSE COMBINATION-ORALLY DISINTEGRATING TABLET (FDC-ODT) STUDIES FOR THE TREATMENT OF TYPE 2 DIABETES OR CARDIOVASCULAR DISEASES-A MINI REVIEW

Journal
Pharmata
Pages
114–124
Publication Date
2022-10-14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this mini-review, I aimed to provide an overview with some studies on FDC-ODTs prepared for cardiovascular diseases and Type 2 diabetes treatments in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The orally disintegrating tablet (ODT) is a dosage form that stands out for its organoleptic elegancy, better patient compliance, rapid disintegration, and rapid onset of action in geriatric, psychiatric, pediatric, paralyzed, and bedridden patients.
📊
Key Findings & Data:Drug combination therapy refers to the concomitant use of two or more drugs used separately or the use of two or more active pharmaceutical ingredients (APIs) in fixed-dose combinations (FDCs) in a single dosage form.
💡
Conclusion & Impact:In this mini-review, I aimed to provide an overview with some studies on FDC-ODTs prepared for cardiovascular diseases and Type 2 diabetes treatments in the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Cardiovascular diseases · fixed-Dose Combination · orally Disintegrating Tablet

Abstract

The orally disintegrating tablet (ODT) is a dosage form that stands out for its organoleptic elegancy, better patient compliance, rapid disintegration, and rapid onset of action in geriatric, psychiatric, pediatric, paralyzed, and bedridden patients. Drug combination therapy refers to the concomitant use of two or more drugs used separately or the use of two or more active pharmaceutical ingredients (APIs) in fixed-dose combinations (FDCs) in a single dosage form. FDC drug products have been developed to target a single disease or multiple diseases/conditions. There have been studies showing that taking FDC drug products may be more effective than using dosage forms containing individual APIs. However, the safety, efficacy, and rationality of many FDCs still remain questionable. Furthermore, FDC-ODTs combine the advantages such as better compliance and efficacy of both FDC and ODTs, especially in dysphagic patients and the patients on multiple drug therapy. FDC-ODTs have been prepared for the treatment of different diseases such as Type 2 diabetes, epilepsy, cardiovascular disease, Parkinson’s disease. In this mini-review, I aimed to provide an overview with some studies on FDC-ODTs prepared for cardiovascular diseases and Type 2 diabetes treatments in the literature.

🔖

Cite This Article

ÇETİN, M. (2022). FIXED-DOSE COMBINATION-ORALLY DISINTEGRATING TABLET (FDC-ODT) STUDIES FOR THE TREATMENT OF TYPE 2 DIABETES OR CARDIOVASCULAR DISEASES-A MINI REVIEW. Pharmata, Cilt: 2 Sayı: 4, 114–124. https://ajindex.com/articles/947927

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hannan PA, Khan JA, Khan A, Safiullah S. Oral dispersible system: A new approach in drug delivery system. Indian J Pharm Sci. 2016;78:2–7.
  2. Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTs): Recent advances and perspectives. BioMed Research International. 2021;e6618934.
  3. Abay F, Ugurlu T. Orally disintegrating tablets: A short review. Journal of Pharmaceutics & Drug Development. 2015;3:303
  4. FDA. Guidance for Industry, Orally Disintegrating Tablets. 2008. Accessed 29 August 2022. Available:
  5. Koner JS, Rajabi-Siahboomi AR, Missaghi S, Kirby D, Perrie Y, Ahmed J, et al. Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets. Sci Rep. 2019;9:12467.
  6. Japanese Pharmacopoeia Eighteenth Edition. Accessed 30 August 2022. Available:
  7. Deepika B, Raju K, Kabeer A, Begum S, Rao K. A review on orally disintegrating tablets. World Journal of Pharmacy and Pharmaceutical Sciences. 2017;6(3):460-475
  8. Comoglu T, Ozyilmaz ED. Orally disintegrating tablets and orally disintegrating mini tablets–novel dosage forms for pediatric use. Pharm Dev Technol. 2019;24(7):902–914.
  9. Rahman M, Islam F, Rahman A, Ahmed T, Uddin MB, Shaheen SM, et al. Present and future prospect of combination drugs therapy. World Journal of Pharmaceutical Research. 2020;9:1625–1638
  10. Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189–1195.
  11. Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013;7:9518–9525.
  12. Güvenç Paltun B, Kaski S, Mamitsuka H. Machine learning approaches for drug combination therapies. Briefings in Bioinformatics. 2021;22(6):bbab293.
  13. Janczura M, Sip S, Cielecka-Piontek J. The development of innovative dosage forms of the fixed-dose combination of active pharmaceutical ingredients. Pharmaceutics. 2022;14(4):834.
  14. FDA. Hypertension: Developing fixed-combination d